Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models

Todd M. Pitts, Gillian N. Kulikowski, Aik-Choon Tan, Brion W. Murray, John J. Arcaroli, John J. Tentler, Anna Spreafico, Heather M. Selby, Maria I. Kachaeva, Kelly L. McPhillips, Blair C. Britt, Erica L. Bradshaw-Pierce, Wells A. Messersmith, Marileila Varella-Garcia, S. Gail Eckhardt

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The p21-activated kinase (PAK) family of serine/threonine kinases, which are overexpressed in several cancer types, are critical mediators of cell survival, motility, mitosis, transcription, and translation. In the study presented here, we utilized a panel of colorectal cancer (CRC) cell lines to identify potential biomarkers of sensitivity or resistance that may be used to individualize therapy to the PAK inhibitor PF-03758309. We observed a wide range of proliferative responses in the CRC cell lines exposed to PF-03758309, this response was recapitulated in other phenotypic assays such as anchorage-independent growth, three-dimensional (3D) tumor spheroid formation, and migration. Interestingly, we observed that cells most sensitive to PF-03758309 exhibited up-regulation of genes associated with a mesenchymal phenotype (CALD1, VIM, ZEB1) and cells more resistant had an up-regulation of genes associated with an epithelial phenotype (CLDN2, CDH1, CLDN3, CDH17) allowing us to derive an epithelial-to-mesenchymal transition (EMT) gene signature for this agent. We assessed the functional role of EMT-associated genes in mediating responsiveness to PF-3758309, by targeting known genes and transcriptional regulators of EMT. We observed that suppression of genes associated with the mesenchymal phenotype conferred resistance to PF-3758309, in vitro and in vivo. These results indicate that PAK inhibition is associated with a unique response phenotype in CRC and that further studies should be conducted to facilitate both patient selection and rational combination strategies with these agents.

Original languageEnglish
Article numberArticle 35
JournalFrontiers in Pharmacology
Volume4 MAR
DOIs
Publication statusPublished - 2013 Aug 21
Externally publishedYes

Fingerprint

p21-Activated Kinases
Epithelial-Mesenchymal Transition
Colonic Neoplasms
Phenotype
Colorectal Neoplasms
Genes
Up-Regulation
Cell Line
Gene Targeting
Protein-Serine-Threonine Kinases
Regulator Genes
Mitosis
Patient Selection
Cell Movement
Neoplasms
Cell Survival
Biomarkers
PF 3758309
Growth

Keywords

  • Colorectal cancer
  • Emt
  • Intrinsic resistance
  • PAK
  • Pf-3758309

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. / Pitts, Todd M.; Kulikowski, Gillian N.; Tan, Aik-Choon; Murray, Brion W.; Arcaroli, John J.; Tentler, John J.; Spreafico, Anna; Selby, Heather M.; Kachaeva, Maria I.; McPhillips, Kelly L.; Britt, Blair C.; Bradshaw-Pierce, Erica L.; Messersmith, Wells A.; Varella-Garcia, Marileila; Eckhardt, S. Gail.

In: Frontiers in Pharmacology, Vol. 4 MAR, Article 35, 21.08.2013.

Research output: Contribution to journalArticle

Pitts, TM, Kulikowski, GN, Tan, A-C, Murray, BW, Arcaroli, JJ, Tentler, JJ, Spreafico, A, Selby, HM, Kachaeva, MI, McPhillips, KL, Britt, BC, Bradshaw-Pierce, EL, Messersmith, WA, Varella-Garcia, M & Eckhardt, SG 2013, 'Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models', Frontiers in Pharmacology, vol. 4 MAR, Article 35. https://doi.org/10.3389/fphar.2013.00035
Pitts, Todd M. ; Kulikowski, Gillian N. ; Tan, Aik-Choon ; Murray, Brion W. ; Arcaroli, John J. ; Tentler, John J. ; Spreafico, Anna ; Selby, Heather M. ; Kachaeva, Maria I. ; McPhillips, Kelly L. ; Britt, Blair C. ; Bradshaw-Pierce, Erica L. ; Messersmith, Wells A. ; Varella-Garcia, Marileila ; Eckhardt, S. Gail. / Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. In: Frontiers in Pharmacology. 2013 ; Vol. 4 MAR.
@article{dffc338548804099ba43172e235e5ed5,
title = "Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models",
abstract = "The p21-activated kinase (PAK) family of serine/threonine kinases, which are overexpressed in several cancer types, are critical mediators of cell survival, motility, mitosis, transcription, and translation. In the study presented here, we utilized a panel of colorectal cancer (CRC) cell lines to identify potential biomarkers of sensitivity or resistance that may be used to individualize therapy to the PAK inhibitor PF-03758309. We observed a wide range of proliferative responses in the CRC cell lines exposed to PF-03758309, this response was recapitulated in other phenotypic assays such as anchorage-independent growth, three-dimensional (3D) tumor spheroid formation, and migration. Interestingly, we observed that cells most sensitive to PF-03758309 exhibited up-regulation of genes associated with a mesenchymal phenotype (CALD1, VIM, ZEB1) and cells more resistant had an up-regulation of genes associated with an epithelial phenotype (CLDN2, CDH1, CLDN3, CDH17) allowing us to derive an epithelial-to-mesenchymal transition (EMT) gene signature for this agent. We assessed the functional role of EMT-associated genes in mediating responsiveness to PF-3758309, by targeting known genes and transcriptional regulators of EMT. We observed that suppression of genes associated with the mesenchymal phenotype conferred resistance to PF-3758309, in vitro and in vivo. These results indicate that PAK inhibition is associated with a unique response phenotype in CRC and that further studies should be conducted to facilitate both patient selection and rational combination strategies with these agents.",
keywords = "Colorectal cancer, Emt, Intrinsic resistance, PAK, Pf-3758309",
author = "Pitts, {Todd M.} and Kulikowski, {Gillian N.} and Aik-Choon Tan and Murray, {Brion W.} and Arcaroli, {John J.} and Tentler, {John J.} and Anna Spreafico and Selby, {Heather M.} and Kachaeva, {Maria I.} and McPhillips, {Kelly L.} and Britt, {Blair C.} and Bradshaw-Pierce, {Erica L.} and Messersmith, {Wells A.} and Marileila Varella-Garcia and Eckhardt, {S. Gail}",
year = "2013",
month = "8",
day = "21",
doi = "10.3389/fphar.2013.00035",
language = "English",
volume = "4 MAR",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models

AU - Pitts, Todd M.

AU - Kulikowski, Gillian N.

AU - Tan, Aik-Choon

AU - Murray, Brion W.

AU - Arcaroli, John J.

AU - Tentler, John J.

AU - Spreafico, Anna

AU - Selby, Heather M.

AU - Kachaeva, Maria I.

AU - McPhillips, Kelly L.

AU - Britt, Blair C.

AU - Bradshaw-Pierce, Erica L.

AU - Messersmith, Wells A.

AU - Varella-Garcia, Marileila

AU - Eckhardt, S. Gail

PY - 2013/8/21

Y1 - 2013/8/21

N2 - The p21-activated kinase (PAK) family of serine/threonine kinases, which are overexpressed in several cancer types, are critical mediators of cell survival, motility, mitosis, transcription, and translation. In the study presented here, we utilized a panel of colorectal cancer (CRC) cell lines to identify potential biomarkers of sensitivity or resistance that may be used to individualize therapy to the PAK inhibitor PF-03758309. We observed a wide range of proliferative responses in the CRC cell lines exposed to PF-03758309, this response was recapitulated in other phenotypic assays such as anchorage-independent growth, three-dimensional (3D) tumor spheroid formation, and migration. Interestingly, we observed that cells most sensitive to PF-03758309 exhibited up-regulation of genes associated with a mesenchymal phenotype (CALD1, VIM, ZEB1) and cells more resistant had an up-regulation of genes associated with an epithelial phenotype (CLDN2, CDH1, CLDN3, CDH17) allowing us to derive an epithelial-to-mesenchymal transition (EMT) gene signature for this agent. We assessed the functional role of EMT-associated genes in mediating responsiveness to PF-3758309, by targeting known genes and transcriptional regulators of EMT. We observed that suppression of genes associated with the mesenchymal phenotype conferred resistance to PF-3758309, in vitro and in vivo. These results indicate that PAK inhibition is associated with a unique response phenotype in CRC and that further studies should be conducted to facilitate both patient selection and rational combination strategies with these agents.

AB - The p21-activated kinase (PAK) family of serine/threonine kinases, which are overexpressed in several cancer types, are critical mediators of cell survival, motility, mitosis, transcription, and translation. In the study presented here, we utilized a panel of colorectal cancer (CRC) cell lines to identify potential biomarkers of sensitivity or resistance that may be used to individualize therapy to the PAK inhibitor PF-03758309. We observed a wide range of proliferative responses in the CRC cell lines exposed to PF-03758309, this response was recapitulated in other phenotypic assays such as anchorage-independent growth, three-dimensional (3D) tumor spheroid formation, and migration. Interestingly, we observed that cells most sensitive to PF-03758309 exhibited up-regulation of genes associated with a mesenchymal phenotype (CALD1, VIM, ZEB1) and cells more resistant had an up-regulation of genes associated with an epithelial phenotype (CLDN2, CDH1, CLDN3, CDH17) allowing us to derive an epithelial-to-mesenchymal transition (EMT) gene signature for this agent. We assessed the functional role of EMT-associated genes in mediating responsiveness to PF-3758309, by targeting known genes and transcriptional regulators of EMT. We observed that suppression of genes associated with the mesenchymal phenotype conferred resistance to PF-3758309, in vitro and in vivo. These results indicate that PAK inhibition is associated with a unique response phenotype in CRC and that further studies should be conducted to facilitate both patient selection and rational combination strategies with these agents.

KW - Colorectal cancer

KW - Emt

KW - Intrinsic resistance

KW - PAK

KW - Pf-3758309

UR - http://www.scopus.com/inward/record.url?scp=84881566303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881566303&partnerID=8YFLogxK

U2 - 10.3389/fphar.2013.00035

DO - 10.3389/fphar.2013.00035

M3 - Article

VL - 4 MAR

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

M1 - Article 35

ER -